68 related articles for article (PubMed ID: 10052026)
1. Influence of baseline values. II: Variations in plasma lipoprotein fractions during doxazosin treatment for hypertension.
Ahaneku JE; Taylor GO; Agbedana EO
Int J Clin Pharmacol Res; 1998; 18(4):165-70. PubMed ID: 10052026
[TBL] [Abstract][Full Text] [Related]
2. Influence of baseline values. I: Effects on plasma total cholesterol and triglyceride levels during doxazosin treatment for hypertension.
Ahaneku JE; Taylor GO; Agbedana EO; Walker O; Salako LA
Int J Clin Pharmacol Res; 1998; 18(4):159-63. PubMed ID: 10052025
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
[TBL] [Abstract][Full Text] [Related]
5. Changes in lipid and lipoprotein values during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
Ahaneku JE; Taylor GO; Agbedana EO; Walker O; Salako LA
J Pak Med Assoc; 1994 Jul; 44(7):166-9. PubMed ID: 7933456
[TBL] [Abstract][Full Text] [Related]
6. INFLUENCE OF BASELINE VALUES ON LIPIDS, LIPOPROTEINS AND FIBRINOLYTIC PARAMETERS DURING TREATMENT OF HYPERTENSION WITH CILNIDIPINE.
Ahaneku JE; Sakata K; Urano T; Takada Y; Takada A
Pharmacol Res; 2000 Jan; 41(1):79-82. PubMed ID: 10712830
[TBL] [Abstract][Full Text] [Related]
7. INFLUENCE OF BASELINE VALUES ON LIPIDS, LIPOPROTEINS AND FIBRINOLYTIC PARAMETERS DURING AMLODIPINE TREATMENT OF HYPERTENSION IN JAPANESE PATIENTS.
Ahaneku JE; Sakata K; Urano T; Takada Y; Takada A
Pharmacol Res; 2000 Jan; 41(1):73-77. PubMed ID: 10712829
[TBL] [Abstract][Full Text] [Related]
8. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
[TBL] [Abstract][Full Text] [Related]
9. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
11. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
[TBL] [Abstract][Full Text] [Related]
12. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation.
Wolfram RM; Brewer HB; Xue Z; Satler LF; Pichard AD; Kent KM; Waksman R
Am J Cardiol; 2006 Sep; 98(6):711-7. PubMed ID: 16950168
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. Canadian Heart Health Surveys Research Group.
Connelly PW; Petrasovits A; Stachenko S; MacLean DR; Little JA; Chockalingam A
Can J Cardiol; 1999 Apr; 15(4):428-33. PubMed ID: 10322252
[TBL] [Abstract][Full Text] [Related]
14. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.
Bersot TP; Pépin GM; Mahley RW
Am Heart J; 2003 Dec; 146(6):1052-9. PubMed ID: 14660998
[TBL] [Abstract][Full Text] [Related]
15. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of serum lipids and serum lipoprotein spectrum in patients with cerebrovascular diseases.
Zhou J; Zhang M; Li XM
Di Yi Jun Yi Da Xue Xue Bao; 2003 Mar; 23(3):262-4. PubMed ID: 12651248
[TBL] [Abstract][Full Text] [Related]
17. The effects of doxazosin on plasma lipid and lipoprotein levels in hypertensive patients.
Ahaneku JE; Taylor GO; Agbedana EO; Walker O; Salako LA
Pharmacol Res; 1994; 30(3):263-72. PubMed ID: 7862620
[TBL] [Abstract][Full Text] [Related]
18. Increased high density lipoprotein cholesterol in adult nephrotic syndrome in Nigeria.
Adigun MO; Agbedana EO; Kadiri S; Taylor GO
Afr J Med Med Sci; 1999; 28(1-2):97-100. PubMed ID: 12953996
[TBL] [Abstract][Full Text] [Related]
19. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
[TBL] [Abstract][Full Text] [Related]
20. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
